Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan.
Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan; Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Setagaya-ku, Tokyo, 156-0057, Japan; Department of Psychiatry, Takatsuki Hospital, Hachioji, Tokyo, 192-0005, Japan.
Redox Biol. 2022 Feb;49:102222. doi: 10.1016/j.redox.2021.102222. Epub 2021 Dec 22.
Methylglyoxal (MG) is a highly reactive α-ketoaldehyde formed endogenously as a byproduct of the glycolytic pathway. To remove MG, various detoxification systems work together in vivo, including the glyoxalase system, which enzymatically degrades MG using glyoxalase 1 (GLO1) and GLO2. Recently, numerous reports have shown that GLO1 expression and MG accumulation in the brain are involved in the pathogenesis of psychiatric disorders, such as anxiety disorder, depression, autism, and schizophrenia. Furthermore, it has been reported that GLO1 inhibitors may be promising drugs for the treatment of psychiatric disorders. In this review, we discuss the recent findings of the effects of altered GLO1 function on mental behavior, especially focusing on results obtained from animal models.
甲基乙二醛(MG)是一种高度反应性的α-酮醛,作为糖酵解途径的副产物在体内形成。为了清除 MG,各种解毒系统在体内协同工作,包括糖氧还蛋白系统,该系统通过糖氧还蛋白 1(GLO1)和 GLO2 酶促降解 MG。最近,许多报道表明,大脑中 GLO1 的表达和 MG 的积累与焦虑症、抑郁症、自闭症和精神分裂症等精神疾病的发病机制有关。此外,有报道称 GLO1 抑制剂可能是治疗精神疾病的有前途的药物。在这篇综述中,我们讨论了 GLO1 功能改变对精神行为的影响的最新发现,特别是侧重于从动物模型中获得的结果。